snowdeal logo

archives archives

{bio,medical} informatics

Tuesday, August 14, 2001

bookmark: connotea :: ::digg ::furl ::reddit ::yahoo::

find rt skeptics saw something entirely different in today's announcement. One fund manager, an Humelated articles. powered by google. Business 2.0 6,160,717,289 Cures for Cancer

"For years, technologists have dreamed that information technology and biotechnology would someday converge into one seamless superscience that could crack the molecular code of disease and yield a gold mine of new treatments and cures. It always seemed so logical, even if it never quite seemed to happen. Some very big names in tech -- Bill Gates ( MSFT ), Paul Allen, and Jim Clark, among others -- for years have been placing bets on so-called convergence companies that promised to exploit the merging of computing and biotech. Allen alone has investments in more than 50 of them, mostly obscure companies that use words like "genomics," "bioinformatics," and "proteomics" to describe what they do. This industry is so new it hasn't settled on a single name yet."

"Now, like a middle-age actor who has just been discovered, convergence has hit the big time. Corporate giants such as IBM ( IBM ) and Compaq ( CPQ ) are pouring $100 million dollops of cash into "life science" projects that mesh computers and biotech."

find rt skeptics saw something entirely different in today's announcement. One fund manager, an Humelated articles. powered by google. GenomeWeb Physiome Buys IBM's Power4-Based Supercomputer, Announces Research Pact

"IBM and Physiome Sciences have entered into a non-exclusive alliance that will combine IBM's supercomputing technology with Physiome?s biological modeling software, the companies announced."

"IBM, which beat out Compaq, Sun Microsystems and other IT giants with broad life-science partnerships, said that its Power4 technology will feature the world's first computer chip containing two processors."

""I was really impressed with their life sciences group," Maida said, explaining why Physiome chose IBM. "I think they keep it fairly quiet that they have these researchers in there. People forget about the research side of IBM.""

redux [06.26.01]
find related articles. powered by google. Forbes IBM's Biotech Resurgence

"In 1998, biotech upstart Celera Genomics needed a supercomputer to help it map the human genome. It didn't turn to IBM , which built 204 of the 500 fastest supercomputers. Both Celera and its academic competition, the Human Genome Project, used machines built by Compaq Computer. Two years later, Compaq is the leading seller of supercomputers to biological researchers.

But IBM noticed that biologists now need microprocessors as much as microscopes. A year ago, it used $100 million to start a division that sells computers, software and services to biotechnology and drug companies. This life sciences division has had some success; pulling into second place behind Compaq, it must do better."

redux [05.21.01]
find related articles. powered by google. Business 2.0 Tech Giants Court The Genome Crowd

"According to scientists, decoding the human genome is the most complicated civilian computational problem ever tackled, and the data generated by genomics has been doubling every six months. Proteomics eventually will generate 100 times more data than genomics and require 1,000-times more computing power.

"We don't need an evolution in computing, we need a revolution . The normal increase in CPU power is just not enough," says Marshall Peterson, vice president of infrastructure development for Celera. "This is what we call Venter's law-it states that biology will outpace Moore's law. Fast makes the difference in the very beginning of a market, but we won't be at this stage for long.""

redux [03.14.01]
find related articles. powered by google. ABCNews.Com The Next Bubble: Is Bioinformatics the Next Big Boom...and Bust?

"The story proclaimed in its lead, "Move over Information Age. Make room for the age of bioinformation." You could picture bleary eyes opening all over the Bay Area. The story went on to note that a San Jose consulting firm was predicting a 10 percent annual growth in the bioinformatics market for years to come; and that the National Science Foundation estimated that 20,000 new jobs in the field would be created in the field in just the next four years.

If that wasn't enough, the rest of the section was filled with page after page of biotech firms listing job openings - in powerful juxtaposition to the endless lists of dot-com layoffs just a few pages earlier. Picture Starbucks spit-takes from Marin to Santa Cruz.

Wow! Rewrite that resumé to emphasize that biology course you took in college. Roll your Aeron chair down to the nearest lab. Trade that black turtleneck for a white lab coat..."

[ rhetoric ]

Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.


[ search ]

[ outbound ]

biospace / genomeweb / bio-it world / scitechdaily / biomedcentral / the panda's thumb / / nodalpoint / flags and lollipops / on genetics / a bioinformatics blog / andrew dalke / the struggling grad student / in the pipeline / gene expression / free association / pharyngula / the personal genome / genetics and public health blog / the medical informatics weblog / linuxmednews / nanodot / complexity digest /

eyeforpharma /

nsu / nyt science / bbc scitech / newshub / biology news net /

informatics review / stanford / bmj info in practice / bmj info in practice /

[ schwag ]

look snazzy and support the site at the same time by buying some snowdeal schwag !

[ et cetera ]

valid xhtml 1.0?

This site designed by
Eric C. Snowdeal III .
© 2000-2005